Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 7
---
 Table 9 in the Financial Performance section of this document.

4. The eleven manufacturing sites in the US (or territories of the US) are:

- Bogart, GA

- Coppell, TX

- Frederick, MD

- Mt Vernon, IN

- Newark, DE

- Philadelphia, PA

- Puerto Rico

- Redwood City, CA

- Rockville, MD

- Santa Monica, CA

- Tarzana, CA

* Opens in May 2025

5. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

6. Effective Jan 1 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: 'Basis of preparation and accounting policy' in the Notes to the Interim Financial Statements

7. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's financial statements.

Revenue drivers

Table 3: Product Revenue by medicine

|                                  | Q1 2025 |         | % Change |     |
|                                  |      $m | % Total |   Actual | CER |
| - Tagrisso                       |   1,679 |      12 |        5 |   8 |
| - Imfinzi                        |   1,261 |       9 |       13 |  16 |
| - Calquence                      |     762 |       6 |        6 |   8 |
| - Lynparza                       |     726 |       5 |        3 |   5 |
| - Enhertu                        |     596 |       4 |       29 |  34 |
| - Zoladex                        |     293 |       2 |        3 |   8 |
| - Truqap                         |     132 |       1 |      >2x | >2x |
| - Imjudo                         |      80 |       1 |       30 |  33 |
| - Datroway                       |       4 |       - |      n/m | n/m |
| -Other                           
 Onc